Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
J Small Anim Pract ; 64(3): 149-160, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36250216

RESUMEN

OBJECTIVES: To evaluate the feasibility and the complications following single or double random mucosal rotating (transposition or interpolation) flaps for the closure of rostral to mid maxillary defects in dogs. MATERIALS AND METHODS: Medical records of dogs treated with single or double random mucosal rotating flaps after maxillectomy for oral lesions or traumatic loss of tissue, were evaluated. Clinical findings, surgery performed, outcome and postoperative complications (major and minor) were extracted. RESULTS: Twenty-six client-owned dogs were retrospectively included. Dogs underwent maxillectomy for canine acanthomatous ameloblastomas (9), oral squamous cell carcinomas (4), peripheral odontogenic fibromas (4), oral melanomas (3), oral fibrosarcomas (2), dentigerous cysts (2) and oral osteosarcoma (1) and trauma resulting in an oronasal fistula (1). Twenty-three dogs underwent a single transposition or interpolation flap and three dogs were treated with a double transposition flap. Postoperative complications, including dehiscence or flap necrosis, occurred in six dogs. CLINICAL SIGNIFICANCE: Random mucosal rotating (transposition or interpolation) flaps are versatile when used to close rostral maxillary defects in dogs. Postoperative complications appear to be more likely when these flaps are used to close mid maxillary defects.


Asunto(s)
Enfermedades de los Perros , Melanoma , Neoplasias de la Boca , Animales , Perros , Enfermedades de los Perros/cirugía , Melanoma/veterinaria , Neoplasias de la Boca/veterinaria , Complicaciones Posoperatorias/veterinaria , Estudios Retrospectivos , Colgajos Quirúrgicos/veterinaria
2.
J Small Anim Pract ; 62(11): 984-991, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34240420

RESUMEN

OBJECTIVES: Report the use, complications and outcome of the superficial temporal axial pattern flap (STA) when used for closure of skin defects localised to the maxillofacial region in dogs and cats. MATERIALS AND METHODS: Multi-centre retrospective cohort study. Medical records of dogs and cats treated with a STA flap for closure of skin defects were reviewed. Information regarding signalment, reason for axial pattern flap use, flap size, flap healing, postoperative complications including need for surgical revision and overall outcome were collected. RESULTS: Nineteen patients were included: nine dogs and 10 cats. Indications for the STA flap included closure of defects following excision of tumours (18/19, 94.7%) and fungal granuloma resection (1/19, 5.2%). 100% flap survival occurred in 17 of 19 flaps (89.4%). Postoperative complications occurred in eight of 19 flaps (42.1%). A major complication of full thickness partial necrosis of the flap occurred in one of 19 cases (5.2%), where the flap length exceeded recommended guidelines. Minor complications related to the flap were seen in four of 19 cases (21%). This included partial thickness flap necrosis, flap oedema and wound discharge. Complications related to the location of surgery (5/19, 26.3%) included mild ectropion, mild exposure of the eye, reduced ability to blink and subcutaneous emphysema. CLINICAL SIGNIFICANCE: The STA flap is a good option for closure of a skin defect localised to the maxillofacial region. STA flaps were associated with a high percentage of survival and a low incidence of major complications.


Asunto(s)
Enfermedades de los Gatos , Enfermedades de los Perros , Procedimientos de Cirugía Plástica , Animales , Enfermedades de los Gatos/cirugía , Gatos , Enfermedades de los Perros/cirugía , Perros , Procedimientos de Cirugía Plástica/veterinaria , Estudios Retrospectivos , Piel , Colgajos Quirúrgicos/veterinaria
3.
Vet J ; 264: 105538, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33012439

RESUMEN

Cellular adaptation to a hypoxic microenvironment is essential for tumour progression and is largely mediated by HIF-1α and hypoxia-regulated factors, including CXCR4, VEGF-A and GLUT-1. In human osteosarcoma, hypoxia is associated with resistance to chemotherapy as well as with metastasis and poor survival, whereas little is known about its role in canine osteosarcoma (cOSA). This study aimed primarily to evaluate the prognostic value of several known hypoxic markers in cOSA. Immunohistochemical analysis for HIF-1α, CXCR4, VEGF-A and GLUT-1 was performed on 56 appendicular OSA samples; correlations with clinicopathological features and outcome was investigated. The second aim was to investigate the in vitro regulation of markers under chemically induced hypoxia (CoCl2). Two primary canine osteosarcoma cell lines were selected, and Western blotting, immunofluorescence and qRT-PCR were used to study protein and gene expression. Dogs with high-grade OSA (35.7%) were more susceptible to the development of metastases (P = 0.047) and showed high HIF-1α protein expression (P = 0.007). Moreover, HIF-1α overexpression (56%) was correlated with a shorter disease-free interval (DFI; P = 0.01), indicating that it is a reliable negative prognostic marker. The in vitro experiments identified an accumulation of HIF-1α in cOSA cells after chemically induced hypoxia, leading to a significant increase in GLUT-1 transcript (P = 0.02). HIF-1α might be a promising prognostic marker, highlighting opportunities for the use of therapeutic strategies targeting the hypoxic microenvironment in cOSA. These results reinforce the role of the dog as a comparative animal model since similar hypoxic mechanisms are reported in human osteosarcoma.


Asunto(s)
Neoplasias Óseas/veterinaria , Hipoxia de la Célula/fisiología , Enfermedades de los Perros/fisiopatología , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/fisiología , Osteosarcoma/veterinaria , Animales , Biomarcadores de Tumor/análisis , Neoplasias Óseas/química , Neoplasias Óseas/fisiopatología , Línea Celular Tumoral , Enfermedades de los Perros/patología , Perros , Femenino , Regulación Neoplásica de la Expresión Génica , Transportador de Glucosa de Tipo 1/análisis , Subunidad alfa del Factor 1 Inducible por Hipoxia/análisis , Inmunohistoquímica/veterinaria , Masculino , Metástasis de la Neoplasia/fisiopatología , Osteosarcoma/química , Osteosarcoma/fisiopatología , Pronóstico , Receptores CXCR4/análisis , Factor A de Crecimiento Endotelial Vascular/análisis
4.
Vet Comp Oncol ; 18(1): 105-116, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31441996

RESUMEN

Local recurrence (LR) is the major concern in the treatment of feline injection-site sarcoma (FISS). Pretreatment leukocyte counts and ratios have been reported as diagnostic and/or prognostic markers in human and canine oncology. The aim of this retrospective study was to explore the prognostic impact on LR and overall survival time (OST) of pretreatment neutrophil-to-lymphocyte ratio (NLR), white blood cell count (WBCC), neutrophil count (NC) and lymphocyte count (LC) in cats with surgically excised FISS. Eighty-two cats with histologically confirmed FISS at first presentation, without distant metastases, and with available pretreatment haematological analyses were retrospectively enrolled. The correlation of NLR, WBCC, NC, LC with tumour variables and patient variables was explored. NLR was correlated with tumour size (P = .004), histological pattern of tumour growth (P = .024) and histotype (P = .029), while WBCC and NC were associated with ulceration (P = .007, P = .011) and pattern of growth (P = .028, P = .004). No significant relationships emerged between LC and any of the considered variables. The impact of NLR, WBCC, NC, LC on LR and OST was then estimated in univariate and multivariate analysis. In univariate analysis, NLR, WBCC and NC were significant prognostic factors for both LR and OST. NLR, WBCC and NC remained prognostic in multivariate analysis for LR but not for OST. When NLR, WBCC and NC were jointly analysed, WBCC was the marker with the greater impact on LR. Preoperative NLR, WBCC and NC may aid in identifying cats at higher risk of LR.


Asunto(s)
Enfermedades de los Gatos/sangre , Recurrencia Local de Neoplasia/veterinaria , Sarcoma/veterinaria , Animales , Enfermedades de los Gatos/cirugía , Gatos , Femenino , Reacción en el Punto de Inyección/veterinaria , Recuento de Leucocitos/veterinaria , Recuento de Linfocitos/veterinaria , Masculino , Recurrencia Local de Neoplasia/sangre , Recurrencia Local de Neoplasia/cirugía , Neutrófilos , Pronóstico , Estudios Retrospectivos , Sarcoma/sangre , Sarcoma/cirugía
5.
J Small Anim Pract ; 60(2): 102-106, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30474219

RESUMEN

OBJECTIVE: To determine the frequency and type of healing complications arising after the use of the caudal auricular axial pattern flap to close defects on the head in dogs and cats. MATERIAL AND METHODS: Multi-centre retrospective cohort study. Centres were recruited by the Association for Veterinary Soft Tissue Surgery Research Cooperative. Medical records of 11 centres were reviewed, and data from all dogs and cats treated with a caudal auricular axial pattern flap were retrieved. The following data were recorded: signalment, reason for reconstruction, flap dimensions, anatomic landmarks used, histological diagnosis, flap healing and whether revision surgery was required. RESULTS: Twenty-eight cases were included: 16 dogs and 12 cats. Flap length: width ratio was approximately 3:1 and flap length extended to the scapular spine in most cases. Optimal wound healing occurred in five of 16 (31%) dogs and six of 12 (50%) cats. Wound dehiscence without flap necrosis occurred in one of 16 (6%) dogs and one of 12 (8%) cats. Wound dehiscence with flap necrosis occurred in 10 of 16 (63%) dogs and five of 12 (42%) cats. Revision surgery was performed in eight of 16 (50%) dogs and three of 12 (25%) cats. CLINICAL SIGNIFICANCE: The caudal auricular axial pattern flap can provide full thickness skin coverage for large defects on the head in dogs and cats. Partial flap necrosis is a common complication, and revision surgery may be required in order to achieve final wound closure.


Asunto(s)
Enfermedades de los Gatos , Enfermedades de los Perros , Animales , Gatos , Estudios de Cohortes , Perros , Estudios Retrospectivos , Colgajos Quirúrgicos , Resultado del Tratamiento
6.
Vet J ; 241: 1-7, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30340654

RESUMEN

Canine oral fibrosarcoma (oFSA) is a malignant, infiltrating, mesenchymal tumour affecting the oral cavity primarily of medium to large middle aged dogs. The diagnosis often is made late in the course of the disease, due to the frequent caudal location of the tumour, and histopathology is not always sufficient to discriminate undifferentiated oFSA from other poorly differentiated malignant mesenchymal tumours occurring at the same site, especially in small biopsy samples. The literature exclusively relating to oFSA is limited and outcome data following treatment are difficult to compare. The purpose of this article is to provide an overview of the literature spanning the last 30 years, specifically with regard to different treatment modalities in their relation to prognosis of canine oFSA. Overall, the survival rate for dogs with oFSA has improved in recent years (overall survival 247-743 days, compared to 30-540days in papers published before 2000), probably due to better surgical planning. The major concern in clinical management of canine oFSA is the high local rate of recurrence (up to 57%), whereas metastasis occurs late in about 10-14% of affected dogs. Wide surgical excision is the mainstay of treatment. Initially, the tumour was considered to be radioresistant, but a combination of surgery and radiotherapy seems to be the most promising treatment modality at present. Despite a histopathological diagnosis of a low-grade tumour, an aggressive treatment approach is always warranted to cure oFSA, but the ability to control local disease still represents the major challenge.


Asunto(s)
Enfermedades de los Perros/mortalidad , Fibrosarcoma/veterinaria , Neoplasias de la Boca/veterinaria , Recurrencia Local de Neoplasia/veterinaria , Animales , Supervivencia sin Enfermedad , Perros , Fibrosarcoma/mortalidad , Neoplasias de la Boca/mortalidad , Recurrencia Local de Neoplasia/mortalidad , Pronóstico
7.
Vet Comp Oncol ; 16(4): 505-510, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29893066

RESUMEN

Metastasis to regional lymph nodes (RLNs) in dogs with cutaneous mast cell tumour (cMCT) has been correlated with shortened survival time and higher risk of spread to distant sites. In the present study, extirpation of non-palpable or normal-sized RLNs was included in the surgical management of cMCT in dogs. Correlations between histological nodal status (HN0-3) and tumour variables were analysed. Ninety-three dogs with single cMCT without distant metastasis that underwent wide surgical excision of the primary tumour and extirpation of non-palpable or normal-sized RLN were included. The association between HN (HN0 vs HN > 0; HN0-1 vs HN2-3) and tumour variables (site, longest diameter, ulceration, 3-tier and 2-tier histological grades) was analysed by a generalized linear model with multinomial error. Then, 33 (35.5%) RLNs were HN0, 14 (15%) were HN1, 26 (28%) were HN2 and 20 (21.5%) were HN3. The presence of positive (HN > 0) RLN was significantly associated with cMCT larger than 3 cm. No other association was statistically significant. Non-palpable/normal-sized RLN in dogs with cMCT can harbour histologically detectable metastatic disease in nearly half of the cases. Extirpation of the RLN should always perfomed to obtain a correct staging of the disease, even in the absence of clinical suspicion of metastasis. Further studies should evaluate the possible therapeutical effect of the tumour burden reduction obtained by exrtipartion of a positive RLN.


Asunto(s)
Enfermedades de los Perros/patología , Escisión del Ganglio Linfático/veterinaria , Mastocitosis Cutánea/veterinaria , Animales , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/cirugía , Perros , Femenino , Ganglios Linfáticos/patología , Metástasis Linfática/patología , Masculino , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/patología , Mastocitosis Cutánea/cirugía , Estadificación de Neoplasias/veterinaria , Estudios Retrospectivos
8.
J Small Anim Pract ; 59(7): 415-421, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29665060

RESUMEN

OBJECTIVE: To describe the use of a caudal superficial epigastric flap in combination with a full-thickness oral mucosal/submucosal graft for single-stage reconstruction of extensive preputial defects in dogs. MATERIALS AND METHODS: Medical records of dogs with extensive preputial defects either of traumatic origin or derived from tumour excision were reviewed. In all dogs, the prepuce was reconstructed using a full-thickness oral mucosal/submucosal graft combined with a caudal superficial epigastric axial pattern flap during a single surgical procedure. Outcome was assessed by routine clinical examinations for 6 months postoperatively, and through telephone follow-up thereafter. RESULTS: Six dogs were included. The caudal superficial epigastric axial pattern flap healed without complications in all dogs, while the full-thickness oral mucosal/submucosal graft failed in one dog. In this individual the skin flap underwent contracture 30 days after surgery and preputial advancement was required. One dog showed postoperative discomfort during urination, which was successfully managed with a Foley catheter and analgesic administration. Three dogs developed paraphimosis at 30, 80 and 90 days, respectively, and required further surgery. Long-term results were good in all dogs. CLINICAL SIGNIFICANCE: The use of a full-thickness oral mucosal/submucosal graft combined with a caudal superficial epigastric axial pattern flap is feasible for single-stage preputial reconstruction in dogs. Attention should be paid to create a sufficiently large preputial opening, in order to prevent paraphimosis.


Asunto(s)
Enfermedades de los Perros/cirugía , Procedimientos de Cirugía Plástica/veterinaria , Procedimientos Quirúrgicos Urológicos Masculinos/veterinaria , Animales , Perros , Masculino , Mucosa Bucal/trasplante , Parafimosis/cirugía , Parafimosis/veterinaria , Complicaciones Posoperatorias/veterinaria , Procedimientos de Cirugía Plástica/métodos , Trasplante de Piel/métodos , Trasplante de Piel/veterinaria , Colgajos Quirúrgicos/veterinaria , Resultado del Tratamiento , Procedimientos Quirúrgicos Urológicos Masculinos/métodos
9.
Vet J ; 224: 1-6, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28697868

RESUMEN

Mast cell tumours (MCTs) in dogs can present in a variety of forms. Non-resectable, recurrent or metastatic MCTs usually carry a poor prognosis and present a therapeutic challenge. Both toceranib and lomustine have shown single agent activity against MCTs in dogs. In this study, 10 dogs with advanced MCTs were enrolled prospectively and treated with toceranib (median dose 2.7mg/kg orally every other day), lomustine (median dose 60mg/m2 orally every 3 weeks) and prednisolone (1mg/kg orally every other day, alternating with toceranib). Severe adverse events (SAEs), requiring alterations in the protocol, occurred in all dogs. The objective response rate was 50%. Three dogs died or were euthanased due to SAEs and therefore enrolment of new dogs was discontinued prematurely. A long term response (>1year) was observed in two dogs. Modifications of the protocol are required for future prospective studies.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Indoles/administración & dosificación , Lomustina/administración & dosificación , Mastocitos/patología , Pirroles/administración & dosificación , Neoplasias Cutáneas/veterinaria , Animales , Antineoplásicos Alquilantes , Enfermedades de los Perros/patología , Perros , Europa (Continente) , Indoles/efectos adversos , Lomustina/efectos adversos , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/veterinaria , Prednisolona/administración & dosificación , Estudios Prospectivos , Pirroles/efectos adversos , Proteínas Tirosina Quinasas Receptoras/antagonistas & inhibidores , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología
10.
Vet Pathol ; 54(3): 405-412, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28438108

RESUMEN

Canine osteosarcoma is highly resistant to current chemotherapy; thus, clarifying the mechanisms of tumor cell resistance to treatments is an urgent need. We tested the geldanamycin derivative 17-AAG (17-allylamino-17-demethoxygeldanamycin) prototype of Hsp90 (heat shock protein 90) inhibitors in 2 canine osteosarcoma cell lines, D22 and D17, derived from primary and metastatic tumors, respectively. With the aim to understand the interplay between cell death, autophagy, and mitophagy, in light of the dual effect of autophagy in regulating cancer cell viability and death, D22 and D17 cells were treated with different concentrations of 17-AAG (0.5 µM, 1 µM) for 24 and 48 hours. 17-AAG-induced apoptosis, necrosis, autophagy, and mitophagy were assessed by transmission electron microscopy, flow cytometry, and immunofluorescence. A simultaneous increase in apoptosis, autophagy, and mitophagy was observed only in the D22 cell line, while D17 cells showed low levels of apoptotic cell death. These results reveal differential cell response to drug-induced stress depending on tumor cell type. Therefore, pharmacological treatments based on proapoptotic chemotherapy in association with autophagy regulators would benefit from a predictive in vitro screening of the target cell type.


Asunto(s)
Antineoplásicos/farmacología , Benzoquinonas/farmacología , Neoplasias Óseas/veterinaria , Enfermedades de los Perros/patología , Lactamas Macrocíclicas/farmacología , Osteosarcoma/veterinaria , Animales , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Benzoquinonas/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/patología , Línea Celular Tumoral , Enfermedades de los Perros/tratamiento farmacológico , Perros , Relación Dosis-Respuesta a Droga , Lactamas Macrocíclicas/uso terapéutico , Microscopía Electrónica de Transmisión/veterinaria , Mitofagia/efectos de los fármacos , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología
11.
J Vet Intern Med ; 31(3): 864-871, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28378427

RESUMEN

BACKGROUND: Osteosarcoma (OSA) should be differentiated from other less frequent primary bone neoplasms, metastatic disease, and tumor-like lesions, as treatment and prognosis can vary accordingly. Hence, a preoperative histologic diagnosis is generally preferred. This requires collection of multiple biopsies under general anesthesia, with possible complications, including pathological fractures. Fine-needle aspiration cytology would allow an earlier diagnosis with a significant reduction of discomfort and morbidity. HYPOTHESIS/OBJECTIVES: The aim of this study was to compare the accuracy of cytological and histologic biopsies in the diagnosis of canine osteodestructive lesions. ANIMALS: Sixty-eight dogs with bone lesions. METHODS: Retrospective study. Accuracy was assessed by comparing the former diagnosis with the final histologic diagnosis on surgical or post-mortem samples or, in the case of non-neoplastic lesions, with follow-up information. RESULTS: The study included 50 primary malignant bone tumors (40 OSAs, 5 chondrosarcomas, 2 fibrosarcomas, and 3 poorly differentiated sarcomas), 6 carcinoma metastases, and 12 non-neoplastic lesions. Accuracy was 83% for cytology (sensitivity, 83.3%; specificity, 80%) and 82.1% for histology (sensitivity, 72.2%; specificity, 100%). Tumor type was correctly identified cytologically and histologically in 50 and 55.5% of cases, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: The accuracy of cytology was similar to histology, even in the determination of tumor type. In no case was a benign lesion diagnosed as malignant on cytology. This is the most important error to prevent, as treatment for malignant bone tumors includes aggressive surgery. Being a reliable diagnostic method, cytology should be further considered to aid decisions in the preoperative setting of canine bone lesions.


Asunto(s)
Enfermedades Óseas/veterinaria , Enfermedades de los Perros/diagnóstico , Animales , Biopsia con Aguja Fina/veterinaria , Enfermedades Óseas/diagnóstico , Enfermedades Óseas/patología , Neoplasias Óseas/diagnóstico , Neoplasias Óseas/patología , Neoplasias Óseas/veterinaria , Huesos/patología , Condrosarcoma/diagnóstico , Condrosarcoma/patología , Condrosarcoma/veterinaria , Diagnóstico Diferencial , Enfermedades de los Perros/patología , Perros , Femenino , Fibrosarcoma/diagnóstico , Fibrosarcoma/patología , Fibrosarcoma/veterinaria , Masculino , Osteosarcoma/diagnóstico , Osteosarcoma/patología , Osteosarcoma/veterinaria , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad
12.
Vet Comp Oncol ; 15(2): 462-469, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26833575

RESUMEN

Canine malignant melanoma (CMM) is the most common canine oral tumour, and up to 70-75% of dogs in stage II-III die within 1 year after surgery. The purpose of this study was to evaluate the expression of platelet-derived growth factors receptors (PDGFR)-α and -ß in stage II and III CMMs and to correlate it with prognosis. PDGFRs expression was evaluated by immunohistochemistry on 48 cases of formalin-fixed CMM samples and correlated with clinical-pathological findings and outcome after surgery. PDGFRs co-expression was observed in 37.5% of cases. Positivity for PDGFR-α and -ß receptor was present in 54.2 and 47.9% of cases, respectively. Ki67 values >19.5% were ascertained in 66.7% of cases. Statistical analysis showed that PDGFRs co-expression and Ki67 values > 19.5% were both associated with worse prognosis. PDGFRs expression suggests a role in the pathogenesis and progression of CMM, and α and ß co-expression appears to be associated to worse prognosis.


Asunto(s)
Enfermedades de los Perros/metabolismo , Melanoma/veterinaria , Neoplasias de la Boca/veterinaria , Receptores del Factor de Crecimiento Derivado de Plaquetas/metabolismo , Animales , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/mortalidad , Perros , Femenino , Regulación Neoplásica de la Expresión Génica , Masculino , Melanoma/diagnóstico , Melanoma/metabolismo , Melanoma/mortalidad , Neoplasias de la Boca/diagnóstico , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/mortalidad , Pronóstico , Receptor alfa de Factor de Crecimiento Derivado de Plaquetas/metabolismo , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/metabolismo , Análisis de Supervivencia
13.
Vet Comp Oncol ; 15(4): 1280-1294, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27578604

RESUMEN

Limited veterinary literature is available regarding prognostic markers for canine renal cell carcinoma (CRCC). We retrospectively evaluated COX-2 expression, histological and clinical features associated with prognosis of CRCC. Sixty-four cases post-nephrectomy were included, 54 had histopathological assessment and 30 had COX-2 immunostaining performed. Eight dogs (13%) had metastatic disease at initial diagnosis. Twenty-seven dogs (42%) received adjuvant therapy after nephrectomy. On univariate analysis, COX-2 expression, mitotic index (MI), histologic type, vascular invasion, neoplastic invasiveness and metastasis at diagnosis were significantly associated with overall median survival time (MST). COX-2 score (COX-2 score > 3 MST 420 days versus 1176 days if COX-2 score <3; P = 0.011) and MI (MI > 30 MST 120 days versus 540 days for MI < 30; P = 0.003) were the only variables associated with CRCC outcome on multivariate analysis. The addition of MI and COX-2 immunostaining to standard histopathological evaluation would help predicting outcome in CRCC patients.


Asunto(s)
Carcinoma de Células Renales/veterinaria , Ciclooxigenasa 2/metabolismo , Enfermedades de los Perros/diagnóstico , Neoplasias Renales/veterinaria , Nefrectomía/veterinaria , Animales , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/cirugía , Enfermedades de los Perros/mortalidad , Enfermedades de los Perros/patología , Enfermedades de los Perros/cirugía , Perros , Femenino , Neoplasias Renales/diagnóstico , Neoplasias Renales/patología , Neoplasias Renales/cirugía , Masculino , Índice Mitótico/veterinaria , Invasividad Neoplásica/patología , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Resultado del Tratamiento
14.
Vet Comp Oncol ; 15(3): 996-1013, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27146852

RESUMEN

Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78-1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75-1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 kg. In vaccinated and non-vaccinated dogs local recurrence rate was 34.8 and 42%, respectively while lung metastatic rate was 39 and 79%, respectively.


Asunto(s)
Proteoglicanos Tipo Condroitín Sulfato/inmunología , Enfermedades de los Perros/terapia , Melanoma/veterinaria , Neoplasias de la Boca/veterinaria , Adyuvantes Inmunológicos/uso terapéutico , Animales , Vacunas contra el Cáncer/uso terapéutico , Terapia Combinada , Enfermedades de los Perros/mortalidad , Perros , Femenino , Masculino , Melanoma/mortalidad , Melanoma/terapia , Neoplasias de la Boca/mortalidad , Neoplasias de la Boca/terapia
15.
J Small Anim Pract ; 56(11): 671-4, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26200699

RESUMEN

Three intact male dogs with stranguria and haematuria caused by uroliths in the penile urethra underwent urethrotomy using a novel surgical approach directly over the caudal part of the os penis because conservative procedures to resolve the obstructions had failed. Haemorrhage was minimal, and the incisions healed rapidly by second intention. Complications did not occur during the 6-month follow-up period. Urethrotomy directly over the os penis is straightforward, associated with few complications and holds promise for the removal of urinary calculi in the penile urethra.


Asunto(s)
Enfermedades de los Perros/cirugía , Pene/cirugía , Uretra/cirugía , Urolitiasis/veterinaria , Animales , Perros , Masculino , Urolitiasis/cirugía
16.
J Small Anim Pract ; 56(6): 370-6, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25736898

RESUMEN

OBJECTIVES: To describe a modified technique of semitendinosus muscle transposition for the repair of ventral perineal hernia. MATERIALS AND METHODS: Retrospective review of case records of dogs with ventral perineal hernia that were treated by transposing the medial half of the longitudinally split semitendinosus muscle of one limb. The transposition of the internal obturator muscle was used when uni- or bilateral rectal sacculation was also present in addition to ventral perineal hernia; colopexy and vas deferens pexy were also performed. RESULTS: Fourteen dogs were included. In addition to ventral perineal hernia, unilateral and bilateral perineal hernia was also present in five and six of the dogs, respectively. The mean follow-up time was 890 days. Ventral perineal hernia was successfully managed by the modified semitendinosus muscle transposition with minor complications in all the dogs included in the study. CLINICAL SIGNIFICANCE: Despite the small number of dogs included, the unilateral transposition of the medial half of the longitudinally split semitendinosus muscle consistently supported the ventral rectal enlargement in perineal hernia without obvious adverse effects.


Asunto(s)
Perros/lesiones , Hernia Ventral/veterinaria , Herniorrafia/veterinaria , Animales , Femenino , Hernia Ventral/cirugía , Herniorrafia/métodos , Miembro Posterior , Masculino , Complicaciones Posoperatorias/veterinaria , Estudios Retrospectivos , Colgajos Quirúrgicos/veterinaria , Resultado del Tratamiento
17.
Vet Comp Oncol ; 13(1): 11-9, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23295011

RESUMEN

The aim of this retrospective study was to describe clinical features, treatment and outcome of 21 dogs with metastatic cancer of unknown primary (MCUP), a biopsy-proven malignancy being diagnosed at a metastatic stage, in which the anatomical origin of the primary tumour cannot be detected. All dogs underwent total-body computed tomography. Signalment, type and duration of clinical signs, metastasis site, pathology results, treatment and outcome were recorded. Carcinoma was the most common diagnosis (57.1%), followed by sarcoma, melanoma and mast cell tumour. The median number of disease sites per dog was 2, with bones, lymph nodes, lungs and spleen being the most frequent metastatic locations. The median survival for all dogs was 30 days. Overall, a primary site was not identified in 20 (95.2%) dogs. MCUP encompasses a variety of different pathologic entities and harbours a poor prognosis.


Asunto(s)
Carcinoma/veterinaria , Enfermedades de los Perros/patología , Mastocitoma/veterinaria , Melanoma/veterinaria , Neoplasias Primarias Desconocidas/veterinaria , Sarcoma/veterinaria , Animales , Neoplasias Óseas/secundario , Neoplasias Óseas/veterinaria , Carcinoma/secundario , Enfermedades de los Perros/mortalidad , Perros , Femenino , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/veterinaria , Linfoma/veterinaria , Masculino , Mastocitoma/secundario , Melanoma/secundario , Estudios Retrospectivos , Sarcoma/secundario , Neoplasias del Bazo/secundario , Neoplasias del Bazo/veterinaria
18.
Res Vet Sci ; 94(1): 90-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22925934

RESUMEN

In humans, the aryl hydrocarbon receptor (AHR) gene battery constitutes a set of contaminant-responsive genes, which have been recently shown to be involved in the regulation of several patho-physiological conditions, including tumorigenesis. As the domestic dog represents a valuable animal model in comparative oncology, mRNA levels of cytochromes P450 1A1, 1A2 and 1B1 (CYP1A1, 1A2 and 1B1), AHR, AHR nuclear translocator (ARNT), AHR repressor (AHRR, whose partial sequence was here obtained) and cyclooxygenase-2 (COX2) were measured in dog control tissues (liver, skin, mammary gland and bone), in 47 mast cell tumors (MCTs), 32 mammary tumors (MTs), 5 osteosarcoma (OSA) and related surgical margins. Target genes were constitutively expressed in the dog, confirming the available human data. Furthermore, their pattern of expression in tumor biopsies was comparable to that already described in a variety of human cancers; in particular, both AHR and COX2 genes were up-regulated and positively correlated, while CYP1A1 and CYP1A2 mRNAs were generally poorly expressed. This work demonstrated for the first time that target mRNAs are expressed in neoplastic tissues of dogs, thereby increasing the knowledge about dog cancer biology and confirming this species as an useful animal model for comparative studies on human oncology.


Asunto(s)
Ciclooxigenasa 2/biosíntesis , Enfermedades de los Perros/metabolismo , Neoplasias/veterinaria , Receptores de Hidrocarburo de Aril/biosíntesis , Animales , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/veterinaria , Enfermedades de los Perros/enzimología , Perros , Femenino , Masculino , Sarcoma de Mastocitos/enzimología , Sarcoma de Mastocitos/metabolismo , Sarcoma de Mastocitos/veterinaria , Neoplasias/enzimología , Neoplasias/metabolismo , Osteosarcoma/enzimología , Osteosarcoma/metabolismo , Osteosarcoma/veterinaria , Reacción en Cadena en Tiempo Real de la Polimerasa/veterinaria
19.
Vet Pathol ; 50(1): 110-21, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22673539

RESUMEN

The expression of Ki67, BCL-2, and COX-2 was investigated in 53 canine cutaneous mast cell tumors (MCTs) by immunohistochemistry and quantitative real time polymerase chain reaction (qPCR) to evaluate their prognostic significance and the association with the histologic grading and the mitotic index (MI). MCTs were graded according to the Patnaik grading system and the novel 2-tier grading system proposed by Kiupel. The numbers of mitotic figures/10 high-power fields (MI) were counted. Both grading systems were significantly associated with prognosis. The Patnaik grading was of limited prognostic value for grade 2 MCTs, with 23% being associated with mortality. The concordance among pathologists was strongly improved by the application of the 2-tier grading system, and 71% of high-grade MCTs were associated with a high mortality rate. MI and Ki67 protein expression were significantly associated with grading and survival. No significant association between BCL-2 protein expression and either grading system or health status was observed. BCL-2 mRNA expression was significantly higher in grade 2 than in grade 1 MCTs, while no statistically significant differences were detected between low- and high-grade MCTs. The increased BCL-2 mRNA level was significantly associated with increased mortality rate. The COX-2 protein expression was detected in 78% of the MCTs investigated. However, neither association with the tumor grade nor with the health status was observed. COX-2 mRNA was significantly up-regulated in MCTs compared to surgical margins and control skin tissue, but it was neither associated with tumor grade nor with survival.


Asunto(s)
Biomarcadores de Tumor/genética , Enfermedades de los Perros/patología , Sarcoma de Mastocitos/veterinaria , Mastocitosis Cutánea/veterinaria , Neoplasias Cutáneas/veterinaria , Animales , Biomarcadores de Tumor/metabolismo , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Enfermedades de los Perros/metabolismo , Perros , Femenino , Estudios de Seguimiento , Regulación Neoplásica de la Expresión Génica , Inmunohistoquímica/veterinaria , Antígeno Ki-67/genética , Antígeno Ki-67/metabolismo , Masculino , Mastocitos/metabolismo , Mastocitos/patología , Sarcoma de Mastocitos/metabolismo , Sarcoma de Mastocitos/patología , Mastocitosis Cutánea/metabolismo , Mastocitosis Cutánea/patología , Índice Mitótico , Clasificación del Tumor/veterinaria , Pronóstico , Estudios Prospectivos , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Piel/metabolismo , Piel/patología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología
20.
Vet Comp Oncol ; 10(3): e1-e29, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22882486

RESUMEN

In preparing this document the Authors aimed to pool current information on canine and feline mast cell disease. The information was gathered from international studies and a emphasis was placed on material and opinion with a strong evidence base. We intend it to form the basis of our understanding in this disease at the current time and we anticipate that it will be particularly useful for the general practitioner. It should be emphasized that the authors are presenting this work from a European perspective.


Asunto(s)
Enfermedades de los Gatos/diagnóstico , Enfermedades de los Perros/diagnóstico , Mastocitosis/veterinaria , Animales , Enfermedades de los Gatos/patología , Enfermedades de los Gatos/terapia , Gatos , Enfermedades de los Perros/patología , Enfermedades de los Perros/terapia , Perros , Mastocitos/patología , Mastocitosis/diagnóstico , Mastocitosis/patología , Mastocitosis/terapia , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/patología , Síndromes Paraneoplásicos/terapia , Síndromes Paraneoplásicos/veterinaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...